The Biological Functions, Structure and Sources of CXCL10 and Its Outstanding Part in the Pathophysiology of Multiple Sclerosis

Reza Vazirinejad^a Zahra Ahmadi^b Mohammad Kazemi Arababadi^c
Gholamhossein Hassanshahi^b Derek Kennedy^d

^aSocial Determinants of Health Research Center, ^bMolecular Medicine Research Center and ^cImmunology of Infectious Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; ^dSchool of Biomolecular and Physical Science, Eskitis Institute for Drug Discovery, Griffith University Nathan, Nathan, Qld., Australia

Key Words

Multiple sclerosis · Chemokine · CXCL10 · Pathogenesis · Inflammation

Abstract

The etiology of several autoimmune diseases, including multiple sclerosis (MS), has still not been completely clarified. MS is defined as an autoimmune disease with clinical features of a chronic, inflammatory and demyelinating autoimmune disorder which affects the central nervous system. The course of the disease includes phases of remission and relapses which can be exacerbated in both severity and duration. Chemokines, which are a subfamily of the cytokines, act as chemoattractants for a wide variety of cells, including immune cells. CXCL10 is a small protein that is defined as an 'inflammatory' chemokine and binds to CXCR3 to mediate immune responses through the activation and recruitment of leukocytes such as T cells, eosinophils, monocytes and NK cells. The aim of this review is to address recent findings regarding the relationship between CXCL10 and MS.

© 2014 S. Karger AG, Basel

Introduction

To date, the etiological aspects of many autoimmune diseases, including multiple sclerosis (MS), has yet to be characterized completely [1]. MS is an inflammatory disorder of the central nervous system (CNS) which is defined by loss of myelin, gliosis and different degrees of axonal and oligodendrocyte pathology [2]. MS usually commences in early adulthood, with paralysis, sensory disturbances, lack of coordination and visual impairment among its most frequent features [3]. The disease often begins with an 'attack' or 'flare' that lasts from a few days to weeks and is followed by remission that most often lasts from a few months to years [4, 5]. The variable course of the disease may be reflected in the differences seen at the morphological level by magnetic resonance imaging and histopathologic evaluations of the CNS, which also vary significantly [6]. Although the main causes of MS are yet to be fully understood, the disease mechanisms are often inferred from the effector phase of an animal model of MS: experimental autoimmune encephalomyelitis (EAE) [7]. The disease course of relaps-

ing-remitting MS (RRMS) involves periods of clinical remission and unpredictable relapses or exacerbations, differing in both severity and duration. Following several years of an RR phase, MS patients may enter a secondary progressive phase (SPMS) where the onset of symptoms and nerve functions gradually worsen either with or without relapses [8].

Although the underlying etiological cause and pathogenesis of MS are unknown, the current suggestions favor MS as an autoimmune inflammatory disorder of the CNS in which autoreactive T lymphocytes recognize CNS-specific proteins, leading to inflammation and demyelination. According to the cellular infiltrates detected in the brain and cerebrospinal fluid (CSF) from patients alongside data from rodent models, including EAE, MS is largely considered to be a CD4⁺ T helper 1 (Th1)-mediated inflammatory disease [9]; however, CD4⁺ Th17 effector T cells are postulated to have more important roles [10, 11]. In the EAE model, it has been demonstrated that the injection of myelin components into susceptible animals resulted in a CD4⁺-mediated autoimmune disease that shares similarities with MS [12]. EAE can also be induced by the adoptive transfer of encephalitogenic CD4⁺ T cells into a naive animal [12, 13]. It appears that white blood cells, including lymphocytes, are chemoattracted to the MS plaques in response to chemokines. Immunohistochemical studies demonstrated that several chemokine ligands, in parallel with their receptors, are present in MS lesions. Therefore, it seems that chemokines play crucial roles in the pathogenesis of MS. Chemokines are a subfamily of the larger family of cytokines that serve as recruiter/migratory factors for a wide spectrum of cells, and their target cells express appropriate transmembrane G protein chemokine receptors. Chemokines are further subdivided into C, CC, CX3C and CXC subgroups according to the position of conserved cysteine motifs in their structure [14]. CXCL10 (interferon- γ -inducible protein 10, previously called IP-10) was initially discovered as a chemokine which is induced by interferon (IFN)- γ and is produced by a wide range of cell types including monocytes [15], neutrophils [16], endothelial cells [17], keratinocytes [18], fibroblasts [19], mesenchymal cells [20], dendritic cells [21], hepatocytes [22] and astrocytes [23]. CXCL10 binds to CXCR3, which is discussed in the next section. Recent evidence has indicated that serum/tissue expression of CXCL10 is increased in MS [24]. Both CXCL10 and CXCR3 are crucial for leukocyte trafficking and homing to inflamed tissues as well as the perpetuation of inflammation which leads to tissue damage [25].

Th1 and Th2 subsets of lymphocytes can be defined by their expression of chemokine receptors. CXCR3 is associated with the Th1 phenotype and is preferentially expressed on activated Th1 cells [26]. MS is considered a Th1-dependent disease in which Th1-related cytokines and chemokines are increased during the course of the disorder [27]. Interestingly, elevated percentages of T cells expressing the CXCR3 chemokine receptor in peripheral blood and CSF during the active phase of MS suggest that CXCR3 plays important roles in the induction of active demyelinating in MS brain lesions [28, 29]. Based on the clinical and experimental observations discussed above, this review explores the relationship between CXCL10 and MS as an autoimmune disorder.

CXCL10 Biostructure and Functions

It is well documented that chemokines – and more specifically CXCL10 – are produced by several cell and tissue types and exhibit pleiotropic effects on a wide range of biological processes including immunity, angiogenesis and organ-specific metastasis of cancers. The role of CXCL10 in these processes makes it a promising therapeutic target for various diseases. However, an identification of the structural properties and mechanism of action of CXCL10 needs to be made if CXCL10 is to be used as a worthwhile therapeutic target for treatment of the aforementioned pathological conditions. CXCL10 was initially identified in human U937 cells (a histiocytic lymphoma cell line with monocytic characterization and origin) and from human placenta and spleen as an IFN- γ -inducible product [30]; mob-1 and crg-2 are the rat and mouse homologs of human chemokine CXCL10, and they share 70 and 78% amino acid homology with these proteins, respectively [31]. Like other members of the chemokine subfamily, CXCL10 is a small-molecular-weight protein (10 kDa) which was functionally described as an ‘inflammatory’ chemokine. Furthermore, the lack the ELR tripeptide (Arg-Leu-Glu) motif in the vicinity of CXC residues characterizes CXCL10 as an inhibitor of neovascularization; hence, it acts as an ‘angiostatic’ (antiangiogenic) chemokine [32]. The CXCL10 gene is located on chromosome 4, contains 4 exons and 3 introns and encodes a protein of 98 amino acids [19, 33]. CXCL10 is transcriptionally regulated in response to external stimuli such as IFN- γ and lipopolysaccharides (LPS) by a region of 230 nucleotides upstream from the transcriptional start site. This area contains several important regulatory elements, as follows: (a) 2 sites for nu-

Fig. 1. External stimuli which affect CXCL10 and the intracellular events leading to its expression (adopted from Ahmadi et al. [30]). Signals are initiated by receptor-ligand interaction, either involving growth factors or cytokines, and stress stimuli are illustrated. Process of receptor binding. Protein complexes are recruited to the receptor. Resulting activation of corresponding signaling events and initiation of activation of their downstream targets. CS = Cytokine stimulation; CRE = cytokine response element; HSRE = HS response element; US = unknown stimulation; ERK = extracellular signal-regulated kinase; I κ B = inhibitor of NF- κ B; JNK = c-Jun N-terminal kinase; MEK = mitogen-activated protein kinase kinase; NIK = NF- κ B-inducing kinase; PI3K = phosphoinositide 3-kinase; UV = ultra violet light.

clear factor- κ B (NF- κ B); (b) 1 site for activator protein 1; (c) 1 site for interferon-stimulated response element (ISRE); and (d) 1 site for binding of heat shock (HS) factors (fig. 1) [34].

CXCL9, CXCL10 and CXCL11 all share CXCR3 as a common receptor for their activities. CXCR3 has two different isoforms: CXCR3-A and CXCR3-B. The most recent studies revealed that the CXCR3 isoforms differentially regulate cell function. The CXCL10/CXCR3-A axis contributes to the induction of chemotaxis and proliferation in various cell types [35, 36], whereas the CXCL10/CXCR3-B axis inhibits migration and proliferation but induces apoptosis [36, 37]. Additionally, CXCL10 is reported to act as an antiangiogenic/antitumor protein [37, 38]. Although the precise biological functions of CXCL10 are yet to be completely identified, several lines of evidence have demonstrated that this chemokine is involved in the following physiological and pathological situations: (a) chemoattraction of macrophages, monocytes and activated T and NK cells [39–41]; (b) modulation of T cell development and function [42, 43]; (c) inhibition of in vitro colony formation by early human bone marrow progenitor cells [44]; (d) stimulation of T cell adhesion to endothelial cells [45]; (e) induction of NK cell migration along with NK cell-

mediated cytotoxicity; (f) in antiangiogenesis (including antitumor angiogenesis) [24, 30, 46], and (g) by mitogenic and chemotactic effects on vascular smooth muscle cells [43, 44].

CXCL10 Signal Transduction

Synergy was observed between tumor necrosis factor (TNF)- α and IFN- γ regarding the induction of CXCL10 expression by different cell systems such as keratinocytes and hepatocytes. This synergistic effect is facilitated by NF- κ B and ISRE in the promoter of CXCL10 [47, 48]. In isolated and cultured pancreatic acinar cells, cholecystokinin (CCK8) was shown to increase CXCL10 via a pathway regulated by NF- κ B activation which was blocked by PDTC (pyrrolidine dithiocarbamate, an NF- κ B inhibitor) through a mechanism which repressed inhibitor of NF- κ B- α degradation and in turn caused induced CXCL10 expression [49]. NF- κ B activation and subsequent CXCL10 expression, in response to CCK8, was reported to be mediated by protein kinase C in parallel with increased intracellular Ca^{2+} [49, 50]. Evidence also indicates that stimulation of keratinocytes with TNF- α and IFN- γ induced CXCL10 in a concentration- and time-

dependent manner, mediated by activation of the protein kinase C pathway [47, 51]. In a similar fashion, primary human kidney mesangial cells, stimulated by TNF- α and/or IFN- γ , also produced CXCL10 in an NF- κ B-dependent pathway, and co-operation between the ISRE and NF- κ B sites on the CXCL10 promoter were responsible for this action [52]. TNF- α and IFN- γ employ STAT1 α (signal transducer and activator of transcription 1 α) and NF- κ B, respectively, for CXCL10 expression in human fibroblast cell lines [47, 52, 53] as well as LPS-stimulated Kupffer cells [54].

Role of CXCL10 in MS

Currently there is limited information available concerning the role of chemokines in MS, especially at the serum level. In MS, chemokines act both as leukocytemigratory factors and mediators of proinflammatory reactions (both of which promote the process of demyelination) [55]. Chemokines regulate the expression of adhesion molecules and therefore aid transendothelial migration of autoreactive immune-compatible cells through the blood-brain barrier [56].

Serum and CSF Levels of CXCL10 in MS Patients

The levels of CXCL10 in circulating blood were previously found to be elevated in IFN- β -treated MS patients when compared with those left untreated [57]. Altered serum levels of other members of the chemokine family such as CCL11 indicated that they are not directly associated with IFN- β treatment and are regulated by Th2 cell-mediated cytokines [58].

Sørensen et al. [59] reported that CXCL10 levels were higher in CSF specimens collected from patients suffering from active MS as opposed to CSF measurements made in neurological subjects with noninflammatory conditions. More than 90% of the T cells present in the CSF of MS patients expressed CXCR3, which is significantly more than those found in peripheral blood. Present observations are in accordance with the fundamental role of the CXCL10/CXCR3 axis in the pathogenesis of MS [29, 59, 60].

Sørensen et al. [61] in another study also revealed that CXCL10 levels were elevated in the CSF of MS patients and that this was associated with increased leukocyte numbers in CSF [61, 62]. It could be reasonable to assume that the induction of CXCL10 (especially in RRMS patients) is probably related to stimulation of regulatory motifs present at the upstream transcriptional start site of

the CXCL10 promoter. This regulatory region of the CXCL10 gene contains motifs for a variety of signal transduction pathways including HS IFN- γ and NF- κ B response elements [63, 64] (fig. 1) [30].

Scarpini et al. [65] assessed CXCL10 in both CSF and serum of RRMS and SPMS patients, but not in primary progressive (PP) MS patients, and observed its elevation. Similarly, Sprenger et al. [66] indicated that CXCL10 was significantly enhanced in the CSF and serum of patients affected by other inflammatory neurological diseases. The results from all these studies are in line with data collected by Franciotta et al. [67] as well as our own data [62], which showed elevated serum levels of CXCL10 in RRMS patients. The increased CXCL10 levels and the increase in cells expressing its receptor, CXCR3, in the CSF of MS patients during the active phase of the disease in the intrathecal compartment have also been well documented [59]. Additionally, Comini-Frota et al. [68] reported that serum CXCL10 levels were higher in MS patients than in controls, and this is interesting because they also recorded considerable increases in expression following 36 h of IFN- β 1a or IFN- β 1b therapy.

Again, studies showed that CXCL10 expression was elevated in the CSF of MS patients and this was associated with demyelination in CNS tissue sections. Furthermore, this was tightly correlated with CXCR3 expression [69]. Christophi et al. [70] reported that quantities of CXCL10 and caspase 1 were both elevated in peripheral blood mononuclear cells of MS patients. However, treatment with either IFN- β 1a formulations (Rebif or Avonex) significantly upregulated the expression of both CXCL10 and caspase 1, which was mediated by the activation of the STAT1 pathway. Moreover, they observed that CXCL10 expression (at the mRNA level) was induced more by the use of Rebif than Avonex. Therefore it appears that in addition to IFN- γ , TNF- α and proinflammatory cytokines CXCL10 is also an IFN- β -inducible gene product involved in MS pathogenesis [61, 71, 72]; however, conflicting reports claimed that chemokine expression was also suppressed by IFN- β [73].

In contrast to the aforementioned studies which documented the elevation of CXCL10 levels in MS patients, Sørensen et al. [61] reported that CXCL10 remained significantly unchanged within the CSF 1 week following fulfillment of a 15-day course of oral high-dose methylprednisolone in MS patients. This does not exclude an effect during or immediately after treatment. However, other effects of methylprednisolone appear to be related to the properties of this compound during the processes of disease remission observed after treatment [74, 75].

Table 1. Summary of the literature reviewed concerning the immune-related diseases reported

Country	Sample size, n	Sex, n	Serum levels of CXCL10	CSF levels of CXCL10	Ref. No.
Denmark	38	21 female 17 male	Patients: 936±72 pg/ml Controls: 319±43 pg/ml	–	59
Denmark	48	ND	–	Patients: 2.6 ng/ml Controls: 319±43 pg/ml (mean±SEM)	61
Denmark	12	ND	–	Patients – with monosymptomatic optic neuritis: 2.1 ng/ml Controls: 1.82 ng/ml	61
Denmark	36	ND	–	Patients – with clinically definite MS: 3.3 ng/ml Controls: 1.82 ng/ml	61
Denmark	26	ND	–	Patients – after 3 weeks in either placebo group: 3.1 ng/ml Controls: 1.82 ng/ml	61
Denmark	22	ND	–	Patients – after 3 weeks in methylprednisolone treatment group: 3.3 ng/ml Controls: 1.82 ng/ml	61
Denmark	10	ND	–	Patients: median of 3.3 ng/ml Controls: 1.82 ng/ml	61
Denmark	10	ND	Patients: median of 0 ng/ml Controls: 1.82 ng/ml	–	61
Italy	39	34 female 5 male	Patients – active RRMS: 289±96 pg/ml (mean±SEM) Controls: 78±15 pg/ml (mean±SEM)	Patients – active RRMS: 453±6 pg/ml (mean±SEM) Controls: 79±27 pg/ml (mean±SEM)	65
Italy	14	13 female 1 male	Patients – stable RRMS: 258±129 pg/ml (mean±SEM) Controls: 78±15 pg/ml (mean±SEM)	Patients – stable RRMS: 293±43 pg/ml (mean±SEM) Controls: 79±27 pg/ml (mean±SEM)	65
Italy	12	8 female 4 male	Patients – SPMS: 221±52 pg/ml (mean±SEM) Controls: 78±15 pg/ml (mean±SEM)	Patients – SPMS: 424±130 pg/ml (mean±SEM) Controls: 79±27 pg/ml (mean±SEM)	65
Italy	9	6 female 3 male	Patients – PPMS: 59±29 pg/ml (mean±SEM) Controls: 78±15 pg/ml (mean±SEM)	Patients – PPMS: 78±15 pg/ml (mean±SEM) Controls: 79±27 pg/ml (mean±SEM)	65
Iran	100	59 female 41 male	Patients: 392 pg/ml Controls: 196 pg/ml	–	62
Italy	25	ND	Patients – stable MS: 69±7 pg/ml Controls: 60±8 pg/ml	Patients – stable MS: 25±2 pg/ml Controls: 22±1 pg/ml	67
Italy	38	ND	Patients – acute MS: 331±66 pg/ml Controls: 60±8 pg/ml	Patients – acute MS: 118±16 pg/ml Controls: 22±1 pg/ml	67
Italy	18	10 female 8 male	Patients – active phase: pretreatment with methylprednisolone 175±95 pg/ml (mean±SEM) Controls: 60±8 pg/ml	Patients – active phase: pretreatment with methylprednisolone 126 ±31 pg/ml (mean±SEM) Controls: 22±1 pg/ml	67
Italy	18	10 female 8 male	Patients – active phase: undergoing therapy with 6-methylprednisolone (1 g daily) after 6 days 102±22 pg/ml (mean±SEM) Controls: 60±8 pg/ml	Patients – active phase: undergoing therapy with 6-methylprednisolone (1 g daily) after 6 days 89±30 pg/ml (mean±SEM) Controls: 22±1 pg/ml	67
Italy	15	9 female 6 mal	Patients – stable phase: pretreatment with IFN-β1a 63±10 pg/ml (mean±SEM) Controls: 60±8 pg/ml	–	67
Italy	15	9 female 6 male	Patients – stable phase: undergoing therapy with IFN-β1a (6 MU weekly) after 6 months 61±11 pg/ml (mean±SEM) Controls: 60±8 pg/ml	–	67

Table 1. (Continued)

Country	Sample size, n	Sex, n	Serum levels of CXCL10	CSF levels of CXCL10	Ref. No.
Denmark	21	17 female 4 male	–	Patients: 1.64 ng/ml Controls: 0.59 ng/ml	69
USA	32	22 female 10 male	Patients – untreated MS: 3.2±1.3 ng/ml Controls: 1±0.2 ng/ml	–	70
USA	10	7 female 3 male	Patients – Rebif MS patients: 12.4±3.3 ng/ml Controls: 1±0.2 ng/ml	–	70
USA	10	7 female 3 male	Patients – Avonex MS patients: 6.3±2.4 ng/ml Controls: 1±0.2 ng/ml	–	70

ND = Not determined.

However, the current observations are in agreement with the prominent role of CXCL10 in the maintenance of intrathecal inflammation and may partly explain the mechanism(s) by which high doses of oral methylprednisolone do not influence the recurrence of disease activity [74]. Thus, treatment with IFN- β appears to be the preferred regime leading to decreased intrathecal inflammation [76].

More recent reports by Møllergård et al. [77] verified that following a period of 1 year of treatment with the newly introduced anti-MS reagent natalizumab, a panel of cytokines and chemokines were decreased. They demonstrated that, in addition to declined levels of proinflammatory cytokines such as interleukin (IL)-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF- α , IFN- δ and granulocyte/macrophage colony-stimulating factor, several chemokines including CXCL9, CXCL10, CXCL11, CCL17 and CCL22 were also decreased in the blood and CSF of RRMS patients following 1 year of treatment with natalizumab.

Expression of CXCL10 in EAE Animal Models and MS Lesions

Astrocytes are also the source of CXCL10 in both human and mouse EAE models [29, 59, 78], and evidence from these models demonstrates that both TNF- α and IFN- γ (as members of the proinflammatory cytokines) regulate CXCL10 expression in cell lines [79] as well as a rat model [48].

Immunocytochemical studies confirmed the presence of CXCL10 in postmortem CNS tissues from MS patients. In lesions where demyelination was active and ongoing, CXCL10 was predominantly expressed by both macrophages (present inside the plaque) and reactive astrocytes

in the surrounding parenchyma. Correspondingly, CXCR3 was also expressed by T cells and astrocytes within the plaques, which may strongly suggest an autocrine fashion of CXCL10 expression by these cells [29, 60].

Salmaggi et al. [80] demonstrated that human brain microvascular endothelial cells and astrocytes express IFN- γ -inducible chemokines CXCL10 and CXCL11 in response to inflammatory stimuli. Moreover, in autoimmune pathologies including MS, both δ T cells (V δ 1 and V δ 2 cells) exhibit differential expression of cell adhesion molecules as well as chemokine receptors. V δ 1 cells express CXCR4, while V δ 2-type cells express CXCR3, and these cell populations transmigrate across endothelial cells in response to CXCL12 and CXCL10 [81]. Buttmann et al. [82] investigated a panel of IFN-inducible chemokines including CXCL10 and, using in situ hybridization analysis, corroborated a strong expression of CXCL10 mRNA by infiltrating immune cells and basal keratinocytes into patients in the IFN- β -injected areas. Table 1 shows a summary of the literature reviewed concerning the immune-related diseases reported.

Conclusions

Overall, based on the latest information available in the literature regarding the role of CXCL10 in the pathogenesis of MS, the authors of the present article propose that CXCL10 plays a critical role during symptomatic inflammatory demyelination events that occur in the pathogenesis of MS. However, this is inconsistent with the evidence that exists regarding the CSF and serum levels of CXCL10 in the PP form of MS, in which less inflamma-

tion is observed [83]. Indeed this is more similar to what is observed in noninflammatory neurological diseases.

Finally, due to the complex manifestations of MS, more characterization – with particular attention to accuracy – is required with regard to surveying several other aspects of the disease. To achieve this, the authors of the present article believe that it is worthwhile to more accurately examine the role of CXCL10 and its corresponding receptor (e.g. CXCR3) during the pathogenesis of MS using animal-based EAE models.

References

- Bach JF, Chatenoud L: Tolerance to islet autoantigens in type 1 diabetes. *Annu Rev Immunol* 2001;19:131–161.
- Rubin SM: Management of multiple sclerosis: an overview. *Dis Mon* 2013;59:253–260.
- Ozakbas S, Kaya D, Idiman E: Early onset multiple sclerosis has worse prognosis than adult onset multiple sclerosis based on cognition and magnetic resonance imaging. *Autoimmune Dis* 2012;2012:563989.
- Lin GY, Wang CW, Chiang TT, Peng GS, Yang FC: Multiple sclerosis presenting initially with a worsening of migraine symptoms. *J Headache Pain* 2013;14:70.
- Rotondi M, Batocchi AP, Coperchini F, Caggiula M, Zerbini F, Sideri R, Leporati P, Nociti V, Frisullo G, Mirabella M: Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion. *Neuroimmunomodulation* 2013;20:341–347.
- Gil Moreno MJ, Cerezo García M, Marasescu R, Pinel González A, López Álvarez L, Aladro Benito Y: Neuropsychological syndromes in multiple sclerosis. *Psicothema* 2013;25:452–460.
- Agrawal SM, Yong VW: Immunopathogenesis of multiple sclerosis. *Int Rev Neurobiol* 2007;79:99–126.
- Gandhi KS, McKay FC, Diefenbach E, Crossett B, Schibeci SD, Heard RN, Stewart GJ, Booth DR, Arthur JW: Novel approaches to detect serum biomarkers for clinical response to interferon- β treatment in multiple sclerosis. *PLoS One* 2010;5:e10484.
- LaSalle JM, Ota K, Hafler DA: Presentation of autoantigen by human T cells. *J Immunol* 1991;147:774–780.
- Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector T_H17 and regulatory T cells. *Nature* 2006;441:235–238.
- Iwakura Y, Ishigame H: The IL-23/IL-17 axis in inflammation. *J Clin Invest* 2006;116:1218–1222.
- Martin R, McFarland HF, McFarlin DE: Immunological aspects of demyelinating diseases. *Annu Rev Immunol* 1992;10:153–187.
- Pettinelli CB, McFarlin DE: Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for $Lyt\ 1+2-$ T lymphocytes. *J Immunol* 1981;127:1420–1423.
- Derakhshan R, Arababadi MK, Ahmadi Z, Karimabad MN, Salehabadi VA, Abedinzadeh M, Khorramdelazad H, Balaei P, Kennedy D, Hassanshahi G: Increased circulating levels of SDF-1 (CXCL12) in type 2 diabetic patients are correlated to disease state but are unrelated to polymorphism of the SDF-1 β gene in the Iranian population. *Inflammation* 2012;35:900–904.
- Ciesielski CJ, Andreakos E, Foxwell BM, Feldmann M: TNF α -induced macrophage chemokine secretion is more dependent on NF- κ B expression than lipopolysaccharides-induced macrophage chemokine secretion. *Eur J Immunol* 2002;32:2037–2045.
- Ohmori Y, Hamilton TA: The interferon-stimulated response element and a κ B site mediate synergistic induction of murine IP-10 gene transcription by IFN- γ and TNF- α . *J Immunol* 1995;154:5235–5244.
- Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH: Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. *J Immunol* 1999;163:6236–6243.
- Dillman JF 3rd, McGary KL, Schlager JJ: An inhibitor of p38 MAP kinase downregulates cytokine release induced by sulfur mustard exposure in human epidermal keratinocytes. *Toxicol In Vitro* 2004;18:593–599.
- Ohmori Y, Hamilton TA: Cell type and stimulus specific regulation of chemokine gene expression. *Biochem Biophys Res Commun* 1994;198:590–596.
- Treacy O, Ryan AE, Heinzl T, O'Flynn L, Cregg M, Wilk M, Odoardi F, Lohan P, O'Brien T, Nosov M, Ritter T: Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation. *PLoS One* 2012;7:e42662.
- Ge MQ, Ho AW, Tang Y, Wong KH, Chua BY, Gasser S, Kemeny DM: NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN- γ and perforin-dependent mechanisms. *J Immunol* 2012;189:2099–2109.
- Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Iqbal J, Hussain MM, Balschun K, Röcken C, Arlt A, Günther R, Hampe J, Schreiber S, Baron JL, Moody DB, Liang TJ, Blumberg RS: Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. *Nat Med* 2012;18:1060–1068.
- Hassanshahi G, Patel SS, Jafarzadeh AA, Dickson AJ: Expression of CXC chemokine IP-10/Mob-1 by primary hepatocytes following heat shock. *Saudi Med J* 2007;28:514–518.
- Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P: Role of chemokines in endocrine autoimmune diseases. *Endocr Rev* 2007;28:492–520.
- Hassanshahi G, Jafarzadeh A, Esmailzadeh B, Arababadi MK, Yousefi H, Dickson AJ: Assessment of NK cells response to hepatocyte derived chemotactic agents. *Pak J Biol Sci* 2008;11:1120–1125.
- Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. *J Exp Med* 1998;187:129–134.
- Arababadi MK, Mosavi R, Khorramdelazad H, Yaghini N, Zarandi ER, Araste M, Pourali R, Nekhei Z, Kennedy D: Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients. *Biomark Med* 2010;4:755–759.

Acknowledgement

This project was supported by a grant from the Rafsanjan University of Medical Sciences.

Disclosure Statement

None of the authors of this study declare any conflict of interest.

- 28 Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. *J Clin Invest* 1999;103:807–815.
- 29 Balashov KE, Rottman JB, Weiner HL, Hancock WW: CCR5⁺ and CXCR3⁺ T cells are increased in multiple sclerosis and their ligands MIP-1 α and IP-10 are expressed in demyelinating brain lesions. *Proc Natl Acad Sci USA* 1999;96:6873–6878.
- 30 Ahmadi Z, Arababadi MK, Hassanshahi G: CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. *Inflammation* 2013;36:364–371.
- 31 Liang P, Averboukh L, Zhu W, Pardee AB: Ras activation of genes: *Mob-1* as a model. *Proc Natl Acad Sci USA* 1994;91:12515–12519.
- 32 Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzau BA, van Damme J, Walz A, Marriotti D, et al: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. *J Biol Chem* 1995;270:27348–27357.
- 33 Deng W, Ohmori Y, Hamilton TA: Mechanisms of IL-4-mediated suppression of IP-10 gene expression in murine macrophages. *J Immunol* 1994;153:2130–2136.
- 34 Ohmori Y, Hamilton TA: Cooperative interaction between interferon (IFN) stimulus response element and κ B sequence motifs controls IFN γ - and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. *J Biol Chem* 1993;268:6677–6688.
- 35 Kelsen SG, Aksoy MO, Yang Y, Shahabuddin S, Litvin J, Safadi F, Rogers TJ: The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 2004;287:L584–L591.
- 36 Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. *J Exp Med* 2003;197:1537–1549.
- 37 Bodnar RJ, Yates CC, Wells A: IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. *Circ Res* 2006;98:617–625.
- 38 Bodnar RJ, Yates CC, Rodgers ME, Du X, Wells A: IP-10 induces dissociation of newly formed blood vessels. *J Cell Sci* 2009;122:2064–2077.
- 39 Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. *J Exp Med* 1993;177:1809–1814.
- 40 Taub DD, Longo DL, Murphy WJ: Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. *Blood* 1996;87:1423–1431.
- 41 Park JW, Gruys ME, McCormick K, Lee JK, Subleski J, Wigginton JM, Fenton RG, Wang JM, Wiltrout RH: Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN- γ (Mig) and chemokine responsive to γ -2 (Crg-2). *J Immunol* 2001;166:3763–3770.
- 42 Laing KJ, Secombes CJ: Chemokines. *Dev Comp Immunol* 2004;28:443–460.
- 43 Wang X, Yue TL, Ohlstein EH, Sung CP, Feuerstein GZ: Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. *J Biol Chem* 1996;271:24286–24293.
- 44 Neville LF, Abdullah F, McDonnell PM, Young PR, Feuerstein GZ, Rabinovici R: *Mob-1* expression in IL-2-induced ARDS: regulation by TNF- α . *Am J Physiol* 1995;269:L884–L890.
- 45 Lloyd AR, Oppenheim JJ, Kelvin DJ, Taub DD: Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. *J Immunol* 1996;156:932–938.
- 46 Kanda N, Watanabe S: Histamine inhibits the production of interferon-induced protein of 10 kDa in human squamous cell carcinoma and melanoma. *J Invest Dermatol* 2002;119:1411–1419.
- 47 Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM: Regulation of human IP-10 gene expression in astrocytoma cells by inflammatory cytokines. *J Neurosci Res* 1998;54:169–180.
- 48 Varley CL, Armitage S, Hassanshahiraviz G, Dickson AJ: Regulation of the C-X-C chemokine, *mob-1*, gene expression in primary rat hepatocytes. *Cytokine* 2003;23:64–75.
- 49 Han B, Logsdon CD: Cholecystokinin induction of *mob-1* chemokine expression in pancreatic acinar cells requires NF- κ B activation. *Am J Physiol* 1999;277(pt 1):C74–C82.
- 50 Han B, Logsdon CD: CCK stimulates *mob-1* expression and NF- κ B activation via protein kinase C and intracellular Ca²⁺. *Am J Physiol Cell Physiol* 2000;278:C344–C351.
- 51 Kaplan G, Luster AD, Hancock G, Cohn ZA: The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. *J Exp Med* 1987;166:1098–1108.
- 52 Romagnani P, Lazzeri E, Lasagni L, Mavilia C, Beltrame C, Francalanci M, Rotondi M, Annunziato F, Maurenzig L, Cosmi L, Galli G, Salvadori M, Maggi E, Serio M: IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. *J Am Soc Nephrol* 2002;13:53–64.
- 53 Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM: p48/STAT-1 α -containing complexes play a predominant role in induction of IFN- γ -inducible protein, 10 kDa (IP-10) by IFN- γ alone or in synergy with TNF- α . *J Immunol* 1998;161:4736–4744.
- 54 Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, Hamilton TA, Vogel SN: Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. *J Immunol* 1999;163:1537–1544.
- 55 Ubogu EE, Cossoy MB, Ransohoff RM: The expression and function of chemokines involved in CNS inflammation. *Trends Pharmacol Sci* 2006;27:48–55.
- 56 Muller DM, Pender MP, Greer JM: Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. *Curr Drug Targets Inflamm Allergy* 2004;3:279–290.
- 57 Buttmann M, Merzyn C, Rieckmann P: Interferon- β induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. *J Neuroimmunol* 2004;156:195–203.
- 58 Gutierrez-Ramos JC, Lloyd C, Gonzalo JA: Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. *Immunol Today* 1999;20:500–504.
- 59 Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. *J Clin Invest* 1999;103:807–815.
- 60 Simpson JE, Newcombe J, Cuzner ML, Woodroffe MN: Expression of the interferon- γ -inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. *Neuropathol Appl Neurobiol* 2000;26:133–142.
- 61 Sørensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM: Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. *Eur J Neurol* 2001;8:665–672.
- 62 Karkamandi H, Hosseini-zijoud S, Hosseini J: Genetic variation at the CXC chemokine IP-10 (CXCL10) in parallel with its increased serum level in south-eastern Iranian multiple sclerosis patients. *AAM* 2012;1:71–76.
- 63 Abousaidi H, Vazirinejad R, Arababadi MK, Rafatpanah H, Pourfathollah AA, Derakhshan R, Daneshmandi S, Hassanshahi G: Lack of association between chemokine receptor 5 (CCR5) δ 32 mutation and pathogenesis of asthma in Iranian patients. *South Med J* 2011;104:422–425.
- 64 Asadikaram G, Asiabanha M, Sayadi A, Jafarzadeh A, Hassanshahi G: Impact of opium on the serum levels of TGF- β in diabetic, addicted and addicted-diabetic rats. *Iran J Immunol* 2010;7:186–192.

- 65 Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, Conti G, Scarlato G: IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. *J Neurol Sci* 2002;195: 41–46.
- 66 Sprenger H, Rösler A, Tonn P, Braune HJ, Hufmann G, Gerns D: Chemokines in the cerebrospinal fluid of patients with meningitis. *Clin Immunol Immunopathol* 1996;80:155–161.
- 67 Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V: Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. *J Neuroimmunol* 2001;115:192–198.
- 68 Comini-Frota ER, Teixeira AL, Angelo JP, Andrade MV, Brum DG, Kaimen-Maciel DR, Foss NT, Donadi EA: Evaluation of serum levels of chemokines during interferon- β treatment in multiple sclerosis patients: a 1-year, observational cohort study. *CNS Drugs* 2011;25:971–981.
- 69 Sørensen TL, Trebst C, Kivisäkk P, Kjae KL, Majmudar A, Ravid R, Lassmann H, Olsen DB, Strieter RM, Ransohoff RM, Sellebjerg F: Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. *J Neuroimmunol* 2002; 127:59–68.
- 70 Christophi GP, Christophi JA, Gruber RC, Mihai C, Mejico LJ, Massa PT, Jubelt B: Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN- β 1a treated multiple sclerosis patients. *J Neurol Sci* 2011;307:41–45.
- 71 Satoh J, Nanri Y, Tabunoki H, Yamamura T: Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFN β -responsive genes in peripheral blood lymphocytes in vitro: an implication for IFN β -related adverse effects in multiple sclerosis. *BMC Neurol* 2006;6:18.
- 72 Wandinger KP, Stürzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, McFarland HF, Martin R: Complex immunomodulatory effects of interferon- β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. *Ann Neurol* 2001; 50:349–357.
- 73 Comabella M, Imitola J, Weiner HL, Khoury SJ: Interferon- β treatment alters peripheral blood monocytes chemokine production in MS patients. *J Neuroimmunol* 2002;126:205–212.
- 74 Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J: Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. *Neurology* 1998;51:529–534.
- 75 Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL: Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. *Eur J Neurol* 2000;7:281–289.
- 76 Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownschidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al: Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFN- β 1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. *J Neuroimmunol* 1999;93:8–14.
- 77 Møllergård J, Edström M, Vrethem M, Ernerudh J, Dahle C: Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. *Mult Scler* 2010;16:208–217.
- 78 Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA, Estes ML, Thomas DM, Tuohy VK: Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. *FASEB J* 1993;7:592–600.
- 79 Azin H, Vazirinejad R, Ahmadabadi BN, Khorramdelazad H, Zarandi ER, Arababadi MK, Karimabad MN, Shamsizadeh A, Rafatpanah H, Hassanshahi G: The SDF-1 3' A genetic variation of the chemokine SDF-1 α (CXCL12) in parallel with its increased circulating levels is associated with susceptibility to MS: a study on Iranian multiple sclerosis patients. *J Mol Neurosci* 2012;47:431–436.
- 80 Salmaggi A, Gelati M, Dufour A, Corsini E, Pagano S, Baccalini R, Ferrero E, Scabini S, Silei V, Ciusani E, de Rossi M: Expression and modulation of IFN- γ -inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. *J Interferon Cytokine Res* 2002;22: 631–640.
- 81 Poggi A, Catellani S, Fenoglio D, Borsellino G, Battistini L, Zocchi MR: Adhesion molecules and kinases involved in $\gamma\delta$ T cells migratory pathways: implications for viral and autoimmune diseases. *Curr Med Chem* 2007;14: 3166–3170.
- 82 Buttmann M, Goebeler M, Toksoy A, Schmid S, Graf W, Berberich-Siebelt F, Rieckmann P: Subcutaneous interferon- β injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. *J Neuroimmunol* 2005;168:175–182.
- 83 Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI: A comparison of the pathology of primary and secondary progressive multiple sclerosis. *Brain* 1994;117(pt 4):759–765.